Peter W. Janes

La Trobe University — Australia

Neuroscience · Life Sciences

29h-index4.3kcitations65works4.12yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Axon Guidance and Neuronal Signaling(30), HER2/EGFR in Cancer Research(28), Monoclonal and Polyclonal Antibodies Research(18), Glycosylation and Glycoproteins Research(14), Hippo pathway signaling and YAP/TAZ(14)

Publications65 total

ADAM10 Knockout from Human Glioblastoma and Colon Cancer Cells Modulates Diverse Signalling Networks and Inhibits Tumour Growth In Vivo
International Journal of Molecular Sciences·2025Open Access
Data from Characterization of mAb104, a mAb Targeting a Conformationally Exposed, Tumor-Specific Epitope of HER2
2025· 1 citedOpen Access
Figure S7 from Characterization of mAb104, a mAb Targeting a Conformationally Exposed, Tumor-Specific Epitope of HER2
2025Open Access
Supplementary Table 2 from Characterization of mAb104, a mAb Targeting a Conformationally Exposed, Tumor-Specific Epitope of HER2
2025Open Access
Figure S8 from Characterization of mAb104, a mAb Targeting a Conformationally Exposed, Tumor-Specific Epitope of HER2
2025Open Access
Figure S4 from Characterization of mAb104, a mAb Targeting a Conformationally Exposed, Tumor-Specific Epitope of HER2
2025Open Access
Supplementary Table 1 from Characterization of mAb104, a mAb Targeting a Conformationally Exposed, Tumor-Specific Epitope of HER2
2025Open Access
Figure S6 from Characterization of mAb104, a mAb Targeting a Conformationally Exposed, Tumor-Specific Epitope of HER2
2025Open Access
Figure S1 from Characterization of mAb104, a mAb Targeting a Conformationally Exposed, Tumor-Specific Epitope of HER2
2025Open Access
Figure S5 from Characterization of mAb104, a mAb Targeting a Conformationally Exposed, Tumor-Specific Epitope of HER2
2025Open Access
Supplementary Data from Characterization of mAb104, a mAb Targeting a Conformationally Exposed, Tumor-Specific Epitope of HER2
2025Open Access
Figure S2 from Characterization of mAb104, a mAb Targeting a Conformationally Exposed, Tumor-Specific Epitope of HER2
2025Open Access
Figure S3 from Characterization of mAb104, a mAb Targeting a Conformationally Exposed, Tumor-Specific Epitope of HER2
2025Open Access
ADAM Proteases in Cancer: Biological Roles, Therapeutic Challenges, and Emerging Opportunities
Cancers·2025· 7 citedOpen Access
Characterization of mAb104, a mAb Targeting a Conformationally Exposed, Tumor-Specific Epitope of HER2
Molecular Cancer Therapeutics·2025· 1 citedOpen Access
Cancer-associated fibroblasts as therapeutic targets for cancer: advances, challenges, and future prospects
Journal of Biomedical Science·2025· 52 citedOpen Access
An Anti-VEGF-B Antibody Reduces Abnormal Tumor Vasculature and Enhances the Effects of Chemotherapy
Cancers·2024· 11 citedOpen Access
Co-clustering of EphB6 and ephrinB1 in trans restrains cancer cell invasion
Communications Biology·2024· 1 citedOpen Access
Inhibition of EphA3 Expression in Tumour Stromal Cells Suppresses Tumour Growth and Progression
Cancers·2023· 11 citedOpen Access
Supplementary Methods, Tables 1 - 2, Figures 1 - 8 from Targeting EphA3 Inhibits Cancer Growth by Disrupting the Tumor Stromal Microenvironment
2023Open Access
page 1 of 4Next →

Frequent Co-authors

Martin Lackmann(20), Andrew M. Scott(18), Mary E. Vail(12), Linda Hii(8), Carmel Murone(8), Carmen Llerena(8), Dimitar B. Nikolov(7), Lakmali Atapattu(7), Nayanendu Saha(6), Eva Nievergall(6), Ingrid J.G. Burvenich(6), Roger J. Daly(5), Zhanqi Liu(5), Sakshi Arora(5), Laura D. Osellame(5), Hui Gan(5), Adam Parslow(5), Angela Rigopoulos(5), Fiona E. Scott(5), Nancy Guo(5)